Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed by Allopurinol in Adult Patients With Malignancy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01564277
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:42.904116+00:00
Published At
2017-12-08T00:00:00+00:00
Record Updated At
2018-01-09
Results Posted At
2017-12-08
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Burkitt Lymphoma", "de Novo Myelodysplastic Syndromes", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-01-09"
protocolSection.identificationModule.nctId
"NCT01564277"
protocolSection.identificationModule.officialTitle
"Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed by Allopurinol in Adult Patients With Malignancy"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-12-08"

Study condition terms

  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Del(5q) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (protocolSection.conditionsModule.conditions)
  • Blastic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Contiguous Stage II Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • de Novo Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Noncontiguous Stage II Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Previously Treated Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage I Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage III Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Untreated Adult Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Untreated Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.